World Journal of Surgery

, Volume 37, Issue 6, pp 1333–1339 | Cite as

Complementary Use of Resection and Radiofrequency Ablation for the Treatment of Colorectal Liver Metastases: An Analysis of 395 Patients

  • Orhan Agcaoglu
  • Shamil Aliyev
  • Koray Karabulut
  • Galal El-Gazzaz
  • Federico Aucejo
  • Robert Pelley
  • Allan E. Siperstein
  • Eren Berber
Article

Abstract

Background

Liver resection and radiofrequency ablation (RFA) are two surgical options in the treatment of patients with colorectal liver metastases (CLM). The aim of this study was to analyze patient characteristics and outcomes after resection and RFA for CLM from a single center.

Methods

Between 2000 and 2010, 395 patients with CLM undergoing RFA (n = 295), liver resection (n = 94) or both (n = 6) were identified from a prospective IRB-approved database. Demographic, clinical and survival data were analyzed using univariate and multivariate analyses.

Results

RFA patients had more comorbidities, number of liver tumors and a higher incidence of extrahepatic disease compared to the Resection patients. The 5-year overall actual survival was 17 % in the RFA, 58 % in the Resection group (p = 0.001). On multivariate analysis, multiple liver tumors, dominant lesion >3 cm, and CEA >10 ng/ml were independent predictors of overall survival. Patients were followed for a median of 20 ± 1 months. Liver and extrahepatic recurrences were seen in 69 %, and 29 % of the patients in the RFA, and 40 %, and 19 % of the patients in the Resection group, respectively.

Conclusions

In this large surgical series, we described the characteristics and oncologic outcomes of patients undergoing resection or RFA for CLM. By having both options available, we were able to surgically treat a large number of patients presenting with different degrees of liver tumor burden and co-morbidities, and also manage liver recurrences in follow-up.

References

  1. 1.
    McKay A, Dixon E, Taylor M (2006) Current role of radiofrequency ablation for the treatment of colorectal liver metastases. Br J Surg 93:1192–1201PubMedCrossRefGoogle Scholar
  2. 2.
    Wood TF, Rose DM, Chung M et al (2000) Radiofrequency ablation of 231 unresectable hepatic tumors: indications, limitations, and complications. Ann Surg Oncol 7:593–600PubMedGoogle Scholar
  3. 3.
    Siperstein AE, Berber E, Ballem N et al (2007) Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg 246:559–565 discussion 565–567PubMedCrossRefGoogle Scholar
  4. 4.
    Abdalla EK, Vauthey JN, Ellis LM et al (2004) Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg 239:818–825 discussion 825–827PubMedCrossRefGoogle Scholar
  5. 5.
    White RR, Avital I, Sofocleous CT et al (2007) Rates and patterns of recurrence for percutaneous radiofrequency ablation and open wedge resection for solitary colorectal liver metastasis. J Gastrointest Surg 11:256–263PubMedCrossRefGoogle Scholar
  6. 6.
    Aloia TA, Vauthey JN, Loyer EM et al (2006) Solitary colorectal liver metastasis: resection determines outcome. Arch Surg 141:460–466 discussion 466–467PubMedCrossRefGoogle Scholar
  7. 7.
    Belghiti J, Hiramatsu K, Benoist S et al (2000) Seven hundred forty-seven hepatectomies in the 1990s: an update to evaluate the actual risk of liver resection. J Am Coll Surg 191:38–46PubMedCrossRefGoogle Scholar
  8. 8.
    Biasco G, Derenzini E, Grazi G et al (2006) Treatment of hepatic metastases from colorectal cancer: many doubts, some certainties. Cancer Treat Rev 32:214–228PubMedCrossRefGoogle Scholar
  9. 9.
    Berber E, Tsinberg M, Tellioglu G (2008) Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg 12:1967–1972PubMedCrossRefGoogle Scholar
  10. 10.
    Tsinberg M, Tellioglu G, Simpfendorfer CH et al (2009) Comparison of laparoscopic versus open liver tumor resection: a case-controlled study. Surg Endosc 23:847–853PubMedCrossRefGoogle Scholar
  11. 11.
    Jemal A, Murray T, Ward E et al (2005) Cancer statistics (2005) CA Cancer J Clin 55:10–30 [published correction appears in CA Cancer J Clin 55:259]Google Scholar
  12. 12.
    Berber E, Pelley R, Siperstein AE (2005) Predictors of survival after radiofrequency thermal ablation of colorectal cancer metastases to the liver: a prospective study. J Clin Oncol 23:1358–1364PubMedCrossRefGoogle Scholar
  13. 13.
    Jaeck D, Bachellier P, Guiguet M et al (1997) Long-term survival following resection of colorectal hepatic metastases. Association Française de Chirurgie. Br J Surg 84:977–980Google Scholar
  14. 14.
    Minagawa M, Makuuchi M, Torzilli G et al (2000) Extension of the frontiers of surgical indications in the treatment of liver metastases from colorectal cancer: long-term results. Ann Surg 231:487–499PubMedCrossRefGoogle Scholar
  15. 15.
    Kornprat P, Jarnagin WR, DeMatteo RP et al (2007) Role of intraoperative thermoablation combined with resection in the treatment of hepatic metastasis from colorectal cancer. Arch Surg 142:1087–1092PubMedCrossRefGoogle Scholar
  16. 16.
    Wong SL, Mangu PB, Choti MA et al (2010) American Society of Clinical Oncology 2009 clinical evidence review on radiofrequency ablation of hepatic metastases from colorectal cancer. J Clin Oncol 28:493–508PubMedCrossRefGoogle Scholar
  17. 17.
    Park IJ, Kim HC, Yu CS et al (2007) Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. Ann Surg Oncol 15:227–232PubMedCrossRefGoogle Scholar
  18. 18.
    Greene FL, Sobin LH (2002) The TNM system: our language for cancer care. J Surg Oncol 80:119–120PubMedCrossRefGoogle Scholar
  19. 19.
    Saltz LB, Cox JV, Blanke C et al (2000) Irinotecan Study Group. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N Engl J Med 343:905–914PubMedCrossRefGoogle Scholar
  20. 20.
    Saltz LB, Clarke S, Az-Rubio E et al (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 26:2013–2019PubMedCrossRefGoogle Scholar
  21. 21.
    Livraghi T, Solbiati L, Meloni F et al (2003) Percutaneous radiofrequency ablation of liver metastases in potential candidates for resection: the “test-of-time approach”. Cancer 97:3027–3035PubMedCrossRefGoogle Scholar
  22. 22.
    Berber E, Rogers S, Siperstein A (2005) Predictors of survival after laparoscopic radiofrequency thermal ablation of hepatocellular cancer: a prospective study. Surg Endosc 19:710–714PubMedCrossRefGoogle Scholar
  23. 23.
    McKay A, Fradette K, Lipschitz J (2009) Long-term outcomes following hepatic resection and radiofrequency ablation of colorectal liver metastases. HPB Surg 2009:346863PubMedCrossRefGoogle Scholar
  24. 24.
    Popescu I, Alexandrescu S, Croitoru A et al (2009) Strategies to convert to resectability the initially unresectable colorectal liver metastases. Hepatogastroenterology 56(91–92):739–744PubMedGoogle Scholar
  25. 25.
    Leung EY, Roxburgh CS, Leen E et al (2010) Combined resection and radiofrequency ablation for bilobar colorectal cancer liver metastases. Hepatogastroenterology 57:41–46PubMedGoogle Scholar
  26. 26.
    Van der Pool AE, Lalmahomed ZS, de Wilt JH et al (2009) Local treatment for recurrent colorectal hepatic metastases after partial hepatectomy. J Gastrointest Surg 13:890–895PubMedCrossRefGoogle Scholar
  27. 27.
    Viganò L, Ferrero A, Lo Tesoriere R et al (2008) Liver surgery for colorectal metastases: results after 10 years of follow-up. Long-term survivors, late recurrences, and prognostic role of morbidity. Ann Surg Oncol 15:2458–2464PubMedCrossRefGoogle Scholar
  28. 28.
    Fong Y, Fortner J, Sun R et al (1999) Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 230:309–318PubMedCrossRefGoogle Scholar
  29. 29.
    Scheele J, Stangl R, Altendorf-Hofmann A et al (1991) Indicators of prognosis after hepatic resection for colorectal secondaries. Surgery 110:13–29PubMedGoogle Scholar
  30. 30.
    Portier G, Elias D, Bouche O et al (2006) Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24:4976–4982PubMedCrossRefGoogle Scholar
  31. 31.
    Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371(9617):1007–1016PubMedCrossRefGoogle Scholar

Copyright information

© Société Internationale de Chirurgie 2013

Authors and Affiliations

  • Orhan Agcaoglu
    • 1
  • Shamil Aliyev
    • 1
  • Koray Karabulut
    • 1
  • Galal El-Gazzaz
    • 1
  • Federico Aucejo
    • 1
  • Robert Pelley
    • 1
  • Allan E. Siperstein
    • 1
  • Eren Berber
    • 1
  1. 1.Department of General Surgery, and Hematology and OncologyCleveland ClinicClevelandUSA

Personalised recommendations